To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs -- those that address unmet medical needs -- based on fewer trials than usual. But it turns out that many of the pharmaceutical companies fail to conduct follow-up trials to prove the drugs work. Continue reading The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up originally appeared on DailyFinance on Wed, 09 Feb 2011 20:00:00. Filed Under: Health Care , Genzyme Corporation , GlaxoSmithKline , Novartis , Amgen , Eli Lilly Permalink | Tweet this! | Comments